Article Text

Download PDFPDF
Single-inhaler triple therapy for prevention of COPD exacerbations

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A randomised controlled trial has tested the efficacy of triple therapy with a single inhaler containing a long-acting beta2 agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS), as maintenance therapy for preventing exacerbations in people with chronic obstructive pulmonary disease (COPD) over LAMA monotherapy.1

The study included three treatment arms: extrafine beclometasone dipropionate, formoterol fumarate and glycopyrronium bromide (BDP/FF/GB; fixed triple therapy using a single inhaler), tiotropium alone (monotherapy) and BDP/FF plus tiotropium (open triple therapy using two inhalers).1 The open triple therapy arm was included as a control. Eligible …

View Full Text